Asset Details
Do you wish to reserve the book?
Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients
Do you wish to request the book?
Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients
2025
Overview
Background
Antibiotic therapy (ABT)-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors (ICI) therapy. We investigated the association between ABT and real-world overall survival (rwOS) and progression-free survival (rwPFS) in patients with metastatic urothelial carcinoma (mUC) receiving ICI or cisplatin-based chemotherapy (CIS).
Methods
Three thousand, one hundred seventy-nine patients were included from a nationwide electronic health record-derived de-identified database. Three-month landmark Kaplan–Meier methods and log-rank tests were used to estimate rwOS/PFS between treatment modalities based on ABT groups (stratified by exposure, timing, excretion mode, and administration route). Cox proportional models with time-varying coefficients were used to investigate the associations between ABT, treatment modality, and rwOS/PFS.
Results
A total of 402 (27.1%) ICI and 655 (38.6%) CIS patients received ABT (
p
< 0.001). ICI receipt (OR 0.65,
p
< 0.001) and advanced age (OR 0.98,
p
< 0.001) were associated with lower ABT use.
ICI exclusive findings included a negative correlation with rwOS in patients who received post-treatment initiated (ICI median: pre—13.2 vs post—7.9 vs none—13.3 months;
p
= 0.009), oral (median oral—9.6 vs none—13.3 months,
p
= 0.03), and renally cleared (median renal—9.9 vs none—13.3 months,
p
= 0.04) ABT.
ABT’s effect was negatively associated with rwOS in ICI patients within first 6 months (HR 1.36, 95% CI 1.107–1.74,
p
= 0.01) but not thereafter (
p
= 0.7).
Conclusions
This study identified a potential ICI-specific negative correlation between ABT and rwOS in patients with mUC, specifically those exposed to ABT pills and receipt before treatment initiation. These results emphasize the importance of antibiotic stewardship and continued investigation of the role of gut microbiome in mUC treatment efficacy.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Analysis
/ Anti-Bacterial Agents - adverse effects
/ Anti-Bacterial Agents - therapeutic use
/ Cancer
/ Carcinoma, Transitional Cell - drug therapy
/ Carcinoma, Transitional Cell - mortality
/ Cisplatin-based chemotherapy
/ Dysbiosis - chemically induced
/ Female
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - therapeutic use
/ Male
/ Medicine
/ Metastatic urothelial carcinoma
/ Microbiota (Symbiotic organisms)
/ Patients
/ Surgery
/ Survival
/ Urologic Neoplasms - drug therapy
/ Urologic Neoplasms - mortality
